Eloxx submits IND for ELX-02 in Alport syndrome; Phase 2 data show remission in 1 of 3 patients

Eloxx Pharmaceuticals, Inc.

Submitted IND to FDA for ELX-02 to treat Alport syndrome with nonsense mutations.
Phase 2 open-label trial: Patient 4401-02 achieved remission with UPCR improving from 1,646 to 850 mg/g during treatment.
Two other patients (4401-01, 4402-01) did not achieve remission; UPCR increased post-treatment.
Data show on-treatment remission in one patient, confirming drug activity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.